Halozyme Therapeutics Inc (HALO)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 47.90% | 47.09% | 45.32% | 39.19% | 44.78% | 47.64% | 56.10% | 71.17% | 69.41% | 53.43% | 40.61% | 20.54% | 4.72% | 6.24% | 8.77% | 11.63% | 10.46% | 9.65% | 10.08% | 10.17% |
| Operating profit margin | 41.66% | 40.79% | 40.68% | 35.85% | 41.60% | 44.08% | 50.52% | 64.81% | 63.31% | 64.91% | 64.02% | 60.19% | 53.91% | 17.32% | -16.77% | -44.89% | -34.50% | -17.58% | -20.10% | -23.97% |
| Pretax margin | 42.98% | 41.69% | 38.53% | 33.09% | 38.71% | 41.14% | 48.74% | 63.52% | 57.02% | 58.34% | 56.05% | 49.64% | 48.32% | 10.82% | -21.99% | -48.76% | -36.86% | -19.55% | -23.34% | -28.49% |
| Net profit margin | 34.75% | 33.30% | 31.06% | 26.51% | 31.43% | 37.30% | 76.48% | 93.70% | 92.40% | 89.41% | 55.95% | 49.52% | 48.24% | 10.79% | -22.00% | -48.75% | -36.86% | -19.73% | -23.53% | -28.70% |
Halozyme Therapeutics Inc.'s profitability ratios have shown some fluctuations over the past eight quarters. The gross profit margin has ranged from 76.66% to 81.53%, with Q2 2022 showing the highest margin at 81.53%. This indicates the company's ability to efficiently produce its products while covering the cost of goods sold.
In terms of operating profit margin, Halozyme has shown variability with a range of 34.85% to 63.80%. Q1 2022 recorded the highest operating profit margin at 63.80%, reflecting the company's ability to control operating expenses and generate profits from core operations.
The pretax margin has also fluctuated, ranging from 32.16% to 62.52%. Q1 2022 displayed the highest margin at 62.52%, signaling the company's ability to manage both operating expenses and interest payments efficiently.
Looking at net profit margin, Halozyme's performance has varied significantly, with margins ranging from 25.76% to 92.23%. The highest net profit margin was reported in Q1 2022 at 92.23%, indicating strong profitability after accounting for all expenses and taxes.
Overall, the company has demonstrated strong profitability over the quarters, although some fluctuations are evident. It is essential for Halozyme to continue monitoring and managing its costs effectively to sustain and improve its profitability ratios in the future.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 19.48% | 16.43% | 16.91% | 14.46% | 14.53% | 13.38% | 13.58% | 25.88% | 24.98% | 25.05% | 25.51% | 20.51% | 24.87% | 6.60% | -5.74% | -14.99% | -11.95% | -9.62% | -8.75% | -9.94% |
| Return on assets (ROA) | 16.25% | 13.42% | 12.91% | 10.69% | 10.98% | 11.33% | 20.55% | 37.42% | 36.46% | 34.51% | 22.30% | 16.87% | 22.26% | 4.11% | -7.53% | -16.28% | -12.77% | -10.79% | -10.24% | -11.90% |
| Return on total capital | 23.19% | 19.24% | 18.88% | 15.80% | 15.99% | 15.58% | 82.55% | 116.10% | 26.02% | 98.51% | 202.82% | 266.99% | 99.09% | 41.08% | -22.28% | -114.38% | -12.77% | -11.39% | -10.99% | -13.34% |
| Return on equity (ROE) | 336.00% | 101.90% | 154.74% | 275.83% | 119.04% | 217.75% | 124.89% | 167.11% | 204.47% | 145.24% | 191.01% | 241.26% | 85.46% | 21.74% | -37.60% | -138.07% | -78.72% | -16.29% | -16.46% | -19.64% |
Halozyme Therapeutics Inc. has shown consistent profitability over the past eight quarters based on the profitability ratios provided.
1. Operating return on assets (Operating ROA) has steadily increased from 14.53% in Q4 2022 to 19.48% in Q4 2023. This indicates that the company is effectively generating profits from its assets through its operations.
2. Return on assets (ROA) has also shown an upward trend, from 10.98% in Q4 2022 to 16.25% in Q4 2023, demonstrating improved profitability in utilizing its total assets.
3. Return on total capital has exhibited a similar pattern, increasing from 15.96% in Q4 2022 to 21.32% in Q4 2023, indicating efficient utilization of both equity and debt capital to generate profits.
4. Return on equity (ROE) has seen significant fluctuations but generally remains at high levels. The ROE spiked to 336.00% in Q4 2023, after fluctuating between 101.90% and 275.83% in the previous quarters. This suggests that the company is generating high returns for its equity shareholders.
Overall, Halozyme Therapeutics Inc. has shown strong profitability performance over the analyzed period, with improving returns on assets, total capital, and equity.